GG's DD, oh & NoMo's 2

[GGraessle]

Press Release Source: Nova BioGenetics


Nova BioGenetics Wraps up 10K-SB, Expects to Submit before Deadline
Monday November 10, 2:19 pm ET


ATLANTA--(BUSINESS WIRE)--Nov. 10, 2003--Nova BioGenetics (OTC Bulletin Board: NVBGE - News) announces it is wrapping up its 10K-SB and should file in time for the deadline. Although the company has worked diligently to complete the 10K-SB prior to now, efforts required for the reverse merger delayed the Company's' filing. Additionally, upon completion of the 10K-SB the quarterly filing will follow shortly behind the 10K-SB and will combine the two Companyies as one, since the completion and reverse of the common stock was accomplished after June 30, 2003.
About Nova BioGenetics:

Nova BioGenetics, Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed. While the company is specifically focused on its biopharmaceutical interests and is presently in a development stage, Nova also operates a division within the company that is responsible for the sale of cutting edge patented and EPA approved antimicrobials and biocides.

Further information on Nova and its line of products can be found by visiting the company's web site at http://www.NovaBioGenetics.com, Ph.# 770-650-6508, Fax # [phone], or for investor information, contact Todd Smith, Dir. of Investor Relations and Secretary / Treasurer.



--------------------------------------------------------------------------------
Contact:
Nova BioGenetics, Atlanta
Todd Smith, 770/650-6508
[e-mail]



--------------------------------------------------------------------------------
Source: Nova BioGenetics